Results testing the efficiency of divalent vaccine against Rhinopneuvmonia and Salmonella abortion of horses
Rhinopneumonia and horse Salmonella abortion, which lead to infectious abortions in mares, cause great economic damage to herd horse breeding. Specific prophylaxis of associated vaccines remains unsolved. Although there are separate vaccines against rhinopneumonia and Salmonella abortion. Preclinical trials of divalent vaccine showed sufficient immunogenicity in laboratory mice. The goal has been set to develop a new vaccine: to test the effectiveness of the associated vaccine on mares. An experimental series of vaccines was developed in conjunction with the department of virology of the All-Russian Institute of Experimental Veterinary Medicine named after Kovalenko Y.R. and Yakut Scientific Research Institute of Agriculture. The associated vaccine is made from the strain SV/ 69 of the Rhinopneumonia virus and the strain of the bacteria Salmonella abortus equi BN-12 with the addition of an immunomodulator, the culture fluid (centrate) from the strain of the bacteria Bacillus subtilis TNP-3. The vaccine is administered once. There were performed hematological and biochemical studies before and after vaccination. Phagocytic activity of blood neutrophils and lysozyme and bactericidal activity of blood sera of pregnant mares were determined. The production of antibodies to the rhinopneumonia virus was investigated by ELISA. Production tests were conducted in 6 farms of 4 districts Republic of Sakha (Yakutia) in 2010-2013 yy. disadvantaged in rhinopneumonia and Salmonella abortion. After vaccination with bivalent vaccine against rhinopneumonia and salmonella abortion of horses, business output of foals in OJSC "Nam" was 78,0 %, SUE EPF "Krasnaya Zvezda" - 79,0 %, APC "Chychymah" - 66,0 %, APC "Uruye" - 53,0 %, EPF "Mandiginskaya" - 50-68,2 %, APC named after "Strod I."- 83,3 %. Immunization of mares causes the production of specific antibodies in high titers, stimulates immunobiological reactivity. As a result, immunity of high tension develops and business output of foals increases by 10,0-24,1 %. A new vaccine should be submitted to the Rosselkhoznadzor for approval.